Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical catumaxomab for BCG-failed or BCG-intolerant non-muscle-invasive bladder cancer
ChiCTR2100044274Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Dec 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of catumaxomab in non-muscle-invasive bladder cancer (NMIBC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Dose-limiting toxicity incidence and 1-year recurrence rate since first instillation. Started Dec 2020; status: recruiting.
02
Drugs
catumaxomab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ChiCTR2100044274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044274.